Effective apatinib treatment of pleomorphic liposarcoma: A case report

Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2017-08, Vol.96 (33), p.e7771-e7771
Main Authors: Yan, Peng, Sun, Mei-Li, Sun, Yu-Ping, Liu, Chuan-Yong
Format: Article
Language:English
Subjects:
Aged, 80 and over
Clinical Case Report
Disease-Free Survival
Female
Humans
Liposarcoma - drug therapy
Pyridines - administration & dosage
Pyridines - adverse effects
Pyridines - therapeutic use
Quality of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy. The patient was diagnosed as having PLS by biopsy. After a failed chemotherapy, apatinib started to be taken orally 425 mg per day. This patient achieved 3-month progression-free survival (PFS) and a higher quality of life. Meanwhile, this patient suffered grade 2 hypertension and grade 3 hand-foot syndrome (HFS). In this case, apatinib presented good efficacy and safety to treat PLS. Randomized clinical studies are required to confirm the efficacy and safety of apatinib in the treatment of PLS.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000007771